CRISPR Therapeutics (CRSP) Fundamental Analysis: Revenue, Earnings & Valuation

4.75 / 10

Netural

Fundamental analysis rates the stock neutral (4.8/10). Revenue‑MV, Profit‑MV, Cash‑MV and inventory turnover are strong, while current and fixed asset turnover, gross margin and cost‑of‑sales ratios are weak. Overall, the company displays modest financial health, warranting cautious investment.

Analysis Checks(6/10)

Revenue-MV

Value-6.38

Score2/3

Weight20.88%

1M Return8.05%

Inventory turnover ratio

Value106.57

Score3/3

Weight18.07%

1M Return6.65%

Gross profit margin (%)

Value-5982.05

Score1/3

Weight0.70%

1M Return0.36%

Profit-MV

Value0.68

Score2/3

Weight16.99%

1M Return6.36%

Income tax / Total profit (%)

Value-0.63

Score2/3

Weight2.13%

1M Return0.98%

Current assets turnover ratio

Value0.00

Score0/3

Weight-3.17%

1M Return-1.61%

Fixed assets turnover ratio

Value0.01

Score1/3

Weight-2.21%

1M Return-1.13%

Cost of sales ratio (%)

Value6082.05

Score1/3

Weight-11.57%

1M Return-7.30%

Asset-MV

Value-0.55

Score2/3

Weight41.52%

1M Return13.10%

Cash-MV

Value0.03

Score2/3

Weight16.65%

1M Return6.19%

Is CRSP undervalued or overvalued?

CRSP scores 4.75/10 on fundamentals and holds a Fair valuation at present. Backed by its -30.18% ROE, -16569.77% net margin, -7.85 P/E ratio, 2.37 P/B ratio, and -49.08% earnings growth, these metrics solidify its Netural investment rating.